ArticleThe British journal of dermatology2026
Genome-wide meta-analysis in lichen sclerosus identifies 14 genomic risk loci.
Article in The British journal of dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLichen sclerosus (LS) is a common and highly debilitating chronic inflammatory dermatosis that primarily affects genital skin in both females and males. Despite the utility of large genetic studies to reveal pathogenic mechanisms and suggest novel therapeutic targets, the genetic basis of LS remains largely unstudied.
objectiveTo identify genomic loci at which common genetic variation influences LS susceptibility and establish associated pathogenic mechanisms.
methodsSex-stratified genome-wide association studies of genital LS were performed in three European biobanks (UK Biobank, the Trøndelag Health Study [HUNT] and FinnGen). LS cases were primarily identified via linked electronic health records from primary and/or secondary care. In total 6,681 female cases and 407,255 controls were included, with 970 male cases and 331,484 controls. GWAS were combined through fixed-effect meta-analysis. Further analyses to identify putative causal variants and genes were performed, including statistical fine-mapping, functional annotation and assessment of colocalization with gene expression quantitative trait loci (eQTLs).
resultsThe MHC Class II allele HLA-DRB1*12:01 was strongly associated with LS susceptibility in females (OR=2.54, 95%CI=2.28-2.83, P=8.3×10-63) and males (OR=2.30, 95%CI=1.73-3.07, P=1.3×10-8). We found genome-wide significant associations (P<5.0×10-8) at another 12 loci in females, including a potentially causal protein-altering variant in IGFLR1 (rs140952221; OR=0.71, 95% CI=0.67-0.74, P=2.1×10-11). Colocalization with established eQTLs in skin and immune tissues highlighted dysregulated expression of CD247, IL2RB and ALDH2 amongst potential LS pathomechanisms. Evidence was observed for shared genetic effects between the sexes, albeit with diluted effect sizes in males (β=0.42, 95%CI=0.21-0.64, P=9.7×10-5). One further risk locus, at chromosome 5p13.2 was revealed by combined-sex meta-analysis.
conclusionsThis study provides new insight into the pathogenesis of LS by identifying common genetic variation contributing to disease risk and implicating immune-inflammatory and metabolic pathways as potential future drug targets.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.